Pemetrexed

Generic Name: Pemetrexed

Brand Names: Alimta, Ciambra, Pemfexy, Pemrydi Rtu, Pemetrexed Fresenius Kabi, Pemetrexed Baxter, Pemetrexed Krka, Pemetrexed medac, Pemetrexed Accord, Pemetrexed Sandoz, Armisarte (previously Pemetrexed Actavis)

Drug Type: Small Molecule

Chemical Formula: C_₂₀H_₂₁N_₅O_₆

CAS Number: 137281-23-3

Unique Ingredient Identifier: 04Q9AIZ7NO

Background: Pemetrexed is a chemotherapy drug that is manufactured and marketed by Eli Lilly and Company under the brand name Alimta. It is indicated for use in combination with cisplatin for the treatment of patients with malignant pleural mesothelioma whose disease is either unresectable or who are otherwise not candidates for curative surgery. Its use in non-small cell lung cancer has also been investigated. Pemetrexed was first approved by the FDA in February 4, 2004.

Indication: Pemetrexed is indicated for the treatment of the following conditions:

Non-squamous non-small cell lung cancer (NSCLC)

Malignant pleural mesothelioma

Associated Conditions: Metastatic Cervical Cancer, Metastatic Non-squamous Non Small Cell Lung Cancer, Metastatic Urothelial Carcinoma (UC), Ovarian Cancer, Locally advanced nonsquamous non-small cell lung cancer, Recurrent, metastatic Non-squamous Non-small-cell Lung Cancer (NSQ NSCLC), Unresectable Malignant Pleural Mesothelioma (MPM), Unresectable Thymoma

Associated Therapies: Monotherapy

Clinical Trials

A Study Evaluating Furmonertinib Plus Platinum-based Doublet Chemotherapy Versus Osimertinib in Patients With Epidermal Growth Factor Receptor (EGFR) Sensitizing Mutation-Positive Non-squamous Non-Small Cell Lung Cancer (NSCLC) and Brain Metastases

Phase 3

Recruiting

Conditions: NSCLC Patients With Brain Metastasis

Interventions: Drug: Furmonertinib Mesilate Tablets
Drug: Osimertinib Mesylate Tablets
Drug: Carboplatin Injection
Drug: Cisplatin for injection
Drug: Pemetrexed Disodium for Injection

First Posted Date: 2025-05-14

Last Posted Date: 2025-05-14

Lead Sponsor: Allist Pharmaceuticals, Inc.

Target Recruit Count: 380

Registration Number: NCT06970639

Locations: 🇨🇳
Guangdong Provincial People's Hospital, Guangdong, Guangzhou, China

A Study on the Efficacy and Safety of Golidocitinib Combined With Tislelizumab and Chemotherapy as First-line Treatment for Advanced NSCLC

Phase 1

Not yet recruiting

Conditions: NSCLC (Advanced Non-small Cell Lung Cancer)

Interventions: Drug: Tislelizumab
Drug: Pemetrexed
Drug: Cisplatin
Drug: Carboplatin
Drug: Paclitaxel
Drug: Albumin Paclitaxel
Drug: Golidocitinib

First Posted Date: 2025-05-14

Last Posted Date: 2025-05-14

Lead Sponsor: Peking University Cancer Hospital & Institute

Target Recruit Count: 21

Registration Number: NCT06969612

Firmonertinib Versus Platinum Based Chemotherapy as First-line Treatment for NSCLC With EGFR PACC or EGFR l861q Mutation

Phase 3

Recruiting

Conditions: NSCLC (Advanced Non-small Cell Lung Cancer)
EGFR

Interventions: Drug: Firmonertinib Mesilate Tablets
Drug: Pemetrexed Disodium for Injection
Drug: Cisplatin for injection
Drug: Carboplatin Injection

First Posted Date: 2025-05-02

Last Posted Date: 2025-05-02

Lead Sponsor: Allist Pharmaceuticals, Inc.

Target Recruit Count: 300

Registration Number: NCT06956001

Locations: 🇨🇳
Ethics Committee of cancer hospital, Chinese Academy of Medical Sciences, BeiJing, Beijing, China
🇨🇳
Shandong Tumor Hospital, Shandong, Jinan, China

A Phase Ib Study of JMKX001899 in Combination With Other Therapies in Advanced NSCLC Harboring KRAS G12C Mutation

Phase 1

Not yet recruiting

Conditions: NSCLC (Advanced Non-small Cell Lung Cancer)

Interventions: Drug: JMKX001899
Drug: IN10018
Drug: Carboplatin

First Posted Date: 2025-04-27

Last Posted Date: 2025-04-27

Lead Sponsor: Jemincare

Target Recruit Count: 72

Registration Number: NCT06946927

Locations: 🇨🇳
Guangdong Provincial People's Hospital, Guangzhou, Guangdong, China

A Study to Evaluate Two Dosing Regimens of Subcutaneous Nivolumab in Combination With Intravenous Ipilimumab and Chemotherapy in Participants With Previously Untreated Metastatic or Recurrent Non-Small Cell Lung Cancer (NSCLC)

Phase 2

Not yet recruiting

Conditions: Non-Small Cell Lung Cancer

Interventions: Drug: Nivolumab
Drug: Ipilimumab
Drug: Carboplatin
Drug: Paclitaxel
Drug: Pemetrexed
Drug: Cisplatin

First Posted Date: 2025-04-27

Last Posted Date: 2025-05-11

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 76

Registration Number: NCT06946797

Locations: 🇵🇱
Local Institution - 0079, Łódź, Łódzkie, Poland
🇧🇷
Local Institution - 0041, Brasilia, Distrito Federal, Brazil
🇺🇸
Local Institution - 0032, Anchorage, Alaska, United States

and more 45 locations

AK129 Combination Therapy for Advanced Solid Tumors

Phase 1

Not yet recruiting

Conditions: Non-small Cell Lung Cancer Stage IIIB/IV
Head and Neck Squamous Cell Carcinoma (HNSCC)
Colorectal Adenocarcinoma
Advanced Solid Tumors

Interventions: Drug: Pemetrexed
Drug: Cetuximab
Drug: Chemotherapy
Drug: AK129(dose 1)
Drug: Cis-platinum
Drug: Carboplatin
Drug: Paclitaxel
Drug: 5-FU (5-fluorouracil)
Drug: Docetaxel
Drug: AK129(dose 2)
Drug: AK129(RP2D)
Drug: Penpulimab

First Posted Date: 2025-04-24

Last Posted Date: 2025-04-24

Lead Sponsor: Akeso

Target Recruit Count: 230

Registration Number: NCT06943820

Locations: 🇨🇳
Liaoning Cancer Hospital, Shenyang, Liaoning, China

A Study of SYS6010 and Platinum-based Chemotherapy in Patients With EGFR-mutated NSCLC.

Phase 3

Not yet recruiting

Conditions: EGFR-mutated Locally Advanced or Metastatic NSCLC

Interventions: Drug: SYS6010
Drug: Pemetrexed
Drug: Cisplatin
Drug: Carboplatin

First Posted Date: 2025-04-15

Last Posted Date: 2025-04-15

Lead Sponsor: CSPC Megalith Biopharmaceutical Co.,Ltd.

Target Recruit Count: 380

Registration Number: NCT06927986

BBO-11818 in Adult Subjects With KRAS Mutant Cancer

Phase 1

Recruiting

Conditions: Non-Small Cell Lung Cancer
NSCLC
PDAC - Pancreatic Ductal Adenocarcinoma
CRC (Colorectal Cancer)
Metastatic Non-Small Lung Cell Cancer
Metastatic Colorectal Cancer (CRC)
KRAS G12A
KRAS G12C
KRAS G12D
KRAS G12S

Interventions: Drug: BBO-11818
Drug: Pembrolizumab
Drug: Cetuximab
Drug: Platinum chemotherapy (cisplatin or carboplatin)
Drug: Pemetrexed

First Posted Date: 2025-04-08

Last Posted Date: 2025-05-04

Lead Sponsor: TheRas, Inc., d/b/a BridgeBio Oncology Therapeutics

Target Recruit Count: 287

Registration Number: NCT06917079

Locations: 🇺🇸
Sarah Cannon Research Institute at Mary Crowley, Dallas, Texas, United States
🇺🇸
The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
🇺🇸
NEXT Oncology, San Antonio, Texas, United States

and more 1 locations